Beta-amyloid peptides such as Aβ(1-42) are well known for aggregation and can become difficult to handle if reconstitution is not planned carefully. Solvent choice affects whether the peptide remains monomeric, dissolves rapidly, or begins to fibrillize after buffer exchange.
Need help evaluating your sequence?
Use our Peptide Calculator to review sequence features before planning dissolution and aggregation-sensitive experiments.
For additional sequence review, open the Protein/Peptide Property Calculator.
Aβ peptides can form insoluble aggregates during storage or reconstitution, especially if conditions do not control the starting peptide state.
Some solvents dissolve Aβ slowly, while others rapidly generate a soluble starting preparation suitable for later buffer exchange or fibrillation studies.
HFIP is often used to produce a residue of monomeric soluble peptide before reconstitution in the final buffer.
The best dissolution strategy depends on whether you want to maintain soluble peptide, prepare monomer, or induce fibrillation under controlled conditions.
| Approach | Typical use |
|---|---|
| HFIP | Commonly used to solubilize the peptide and leave a monomeric residue after evaporation |
| DMSO | Useful for dissolution, especially before dilution into a working buffer |
| 0.1% aqueous ammonia | Rapid dissolution option in some workflows |
| TRIS·HCl or dilute base | Can be used depending on the specific downstream application |
Start by deciding whether the goal is to prepare a soluble stock, generate a monomeric starting material, or induce fibrillation later. The choice of solvent should support that goal rather than simply dissolve the peptide as quickly as possible.
If your amyloid peptide project requires specific handling or formulation planning, please email sales@lifetein.com or use our quotation form.